Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics

News
Press Releases
- Dec 5, 2022
Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022
- May 30, 2022
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence
- May 27, 2022
Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease
- Nov 11, 2021
Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal Chemistry
- Oct 23, 2020
Inflection Biosciences Announces Publication of Positive Pre-clinical Data for IBL-202 in CLL.
- Oct 19, 2020
Inflection Biosciences Announces Appointment of Gregory I. Berk, MD, to its Board of Directors.
- Jul 30, 2020
Inflection Biosciences Announces Publication of Positive Data for IBL-202 in DLBCL.
- Jun 4, 2020
Inflection Biosciences Announces the Appointment of Professor Martin Dreyling to its Advisory Panel.
- May 12, 2020
Inflection Biosciences Announces Participation at Upcoming Industry Conferences.